Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Triple-negative breast cancer~* Older than 18 years old~* Have tumor resection surgery~* Sufficient organ function (marrow, heart, liver)~Exclusion Criteria:~* Other malignancy~* Other serious disease( marrow, heart, liver)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- EC-T (Type: ACTIVE_COMPARATOR): None
- TP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).